Exelixis (NASDAQ: EXEL) and bluebird bio (NASDAQ: BLUE) are two biotech companies that have been moving in opposite directions on the stock market this year. While Exelixis has provided healthy gains -- its stock is up by 52.1% year to date -- Bluebird's shares have slid by 35.2% since the beginning of the year. With this backdrop in mind, it might be tempting to pick Exelixis as the better stock to buy.
A kidney-cancer drug candidate combining treatments from Bristol-Myers and Exelixis met its primary endpoint of progression-free survival, the companies said. Exelixis shares jumped on the report.
NEW YORK, NY / ACCESSWIRE / May 5, 2020 / Exelixis, Inc. (NASDAQ:EXEL) will be discussing their earnings results in their 2020 First Quarter Earnings call to be held on May 5, 2020 at 5:00 PM Eastern Time. ...
Exelixis : "I've liked this one all the way," said Jim Cramer to a caller during the 'Lightning Round' of Mad Money Thursday night. Exelixis is a genomics-based drug discovery company and the producer of Cometriq, a treatment approved for medullary thyroid cancer with clinical activity in several other types of metastatic cancer. In this daily bar chart of EXEL, below, we can see that prices made a huge upside price gap or void last month.
Exelixis (EXEL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Breakouts beyond key levels of resistance suggest that the bulls are in control of the momentum in the biotech sector.
Exelixis (NASDAQ:EXEL) shares have had a really impressive month, gaining 60%, after some slippage. And the full year...
Exelixis, Inc. (NASDAQ: EXEL) today announced phase 1b clinical trial results for the combination of cabozantinib (CABOMETYX®) and atezolizumab (TECENTRIQ®) in patients with locally advanced or metastatic solid tumors. The data from three expansion cohorts of the COSMIC-021 trial will be presented during the 2020 American Society of Clinical Oncology Virtual Scientific Program (ASCO20). Results from the non-small cell lung cancer (NSCLC) and the metastatic castration-resistant prostate cancer (CRPC) cohorts will be presented as posters, and results from the urothelial carcinoma (UC) cohort will be presented as a poster discussion; all three presentations will be available on demand for ASCO20 registrants beginning Friday, May 29 at 8:00 a.m. ET.
The biotech sector is in focus with pipeline updates from companies evaluating treatments for the novel COVID-19.
Exelixis stock rocketed Monday after the biotech company's Bristol Myers Squibb-partnered kidney cancer treatment succeeded in a Phase 3 test. The duo tested Cabometyx plus Opdivo.
Exelixis shares was roughly unchanged Tuesday, holding gains after a massive 21% jump on Monday amid positive test results for a new cancer medicine. The South San Francisco-based company saw a positive improvement to its IBD Relative Strength (RS) Rating on Tuesday, with an upgrade from 84 to 95. The rating upgrade came after Exelixis and partner Bristol-Myers Squibb on Monday announced positive results in a Phase 3 test of a kidney cancer treatment.
Exelixis, Inc. (Nasdaq: EXEL) today announced that members of Exelixis’ management team will participate in fireside chats at the following virtual investor conferences in May:
Q1 2020 Exelixis Inc Earnings Call
The company's stock soared Monday on results from a late-stage clinical trial pairing with a major cancer immunotherapy.
EXEL earnings call for the period ending March 31, 2020.
Exelixis (EXEL) delivered earnings and revenue surprises of 15.38% and 6.79%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Exelixis (EXEL) beats on earnings and sales in the first quarter and maintains annual outlook amid coronavirus.
Companies In The News Are: CYCC, CODX, NBY, EXEL
Exelixis, Inc. (Nasdaq: EXEL) announced today that its first quarter 2020 financial results will be released on Tuesday, May 5, 2020 after the markets close. At 5:00 p.m. EDT / 2:00 p.m. PDT, Exelixis management will host a conference call and webcast to discuss the results and provide a general business update. Access to the event is available via the Internet from the company’s website.
Exelixis, Inc. (Nasdaq: EXEL) today reported financial results for the first quarter of 2020 and provided an update on progress toward fulfilling its key corporate objectives, as well as commercial and clinical development milestones.